Clinical and Translational Medicine (Jul 2024)
N‐acetyltransferase 10 facilitates tumorigenesis of diffuse large B‐cell lymphoma by regulating AMPK/mTOR signalling through N4‐acetylcytidine modification of SLC30A9
Abstract
Background Accumulating studies suggested that posttranscriptional modifications exert a vital role in the tumorigenesis of diffuse large B‐cell lymphoma (DLBCL). N4‐acetylcytidine (ac4C) modification, catalyzed by the N‐acetyltransferase 10 (NAT10), was a novel type of chemical modification that improves translation efficiency and mRNA stability. Methods GEO databases and clinical samples were used to explore the expression and clinical value of NAT10 in DLBCL. CRISPER/Cas9‐mediated knockout of NAT10 was performed to determine the biological functions of NAT10 in DLBCL. RNA sequencing, acetylated RNA immunoprecipitation sequencing (acRIP‐seq), LC‐MS/MS, RNA immunoprecipitation (RIP)‐qPCR and RNA stability assays were performed to explore the mechanism by which NAT10 contributed to DLBCL progression. Results Here, we demonstrated that NAT10‐mediated ac4C modification regulated the occurrence and progression of DLBCL. Dysregulated N‐acetyltransferases expression was found in DLBCL samples. High expression of NAT10 was associated with poor prognosis of DLBCL patients. Deletion of NAT10 expression inhibited cell proliferation and induced G0/G1 phase arrest. Furthermore, knockout of NAT10 increased the sensitivity of DLBCL cells to ibrutinib. AcRIP‐seq identified solute carrier family 30 member 9 (SLC30A9) as a downstream target of NAT10 in DLBCL. NAT10 regulated the mRNA stability of SLC30A9 in an ac4C‐dependent manner. Genetic silencing of SLC30A9 suppressed DLBCL cell growth via regulating the activation of AMP‐activated protein kinase (AMPK) pathway. Conclusion Collectively, these findings highlighted the essential role of ac4C RNA modification mediated by NAT10 in DLBCL, and provided insights into novel epigenetic‐based therapeutic strategies.
Keywords
